Thursday, July 11, 2024

CATEGORY

Moderna

Respiratory Syncytial Virus Vaccine mRESVIA by Moderna Receives Positive CHMP Opinion, Awaiting EU Approval

Moderna's novel mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...

Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again

For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...

Respiratory Syncytial Virus Vaccine mResvia Gains FDA Approval, Bolstering Moderna’s Market Position

Respiratory syncytial virus (RSV) vaccine mResvia (formerly mRNA-1345) has secured FDA approval, marking a significant milestone for Moderna as it seeks to diversify its...

FDA Delays Moderna’s Respiratory Syncytial Virus Vaccine Approval; Company Aims for Quick Resolution

Moderna, renowned for its groundbreaking contributions to combatting the COVID-19 pandemic with its innovative vaccines, embarked on a new frontier by venturing into the...

Artificial Intelligence Elevates Moderna’s Pioneering mRNA Medicine Development

Moderna has been a pioneer at the intersection of science, technology, and health, embracing machine learning and artificial intelligence (AI) since its inception to...

Eli Lilly, Novo Nordisk, Moderna and Regeneron Post Strong Quarterly Earnings Owing to Successful Development Initiatives

Eli Lilly, Novo Nordisk, Moderna, and Regeneron achieved robust quarterly earnings, attributing it to the success of their drug and pipeline development initiatives. Eli...

Moderna and Caris Life Sciences Join Forces for Advancement in mRNA-Based Oncology Therapeutics Using Health Data

An agreement has been reached where Moderna will use Caris Life Sciences' library of de-identified, multi-modal health data solutions. These solutions have been generated...

Latest news